Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients

Table 2

Patients’ characteristics with the BCSC expression.

	BCSC (CD44+ve and CD24−ve) 32 patients	Non-BCSC 44 patients
Premenopausal	22 (68.8%)	21 (47.7%)	0.1
Postmenopausal	10 (31.2%)	23 (52.3%)
Grade II	4 (12.5%)	26 (59.1%)	0.001
Grade III	28 (87.5%)	18 (40.9%)
Luminal A and B	10 (31.2%)	30 (68.2%)	0.006
Her2-amplified	7 (21.9%)	5 (11.4%)
Triple negative	15 (46.9%)	9 (20.4%)
CR, PR, and SD	5 (16.1%)	22 (51.2%)	0.003
Progressed disease	26 (83.9%)	21 (48.8%)